View Older Stories

Jan 15, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jan 12, 2026 07:54AM Beam Therapeutics (BEAM) Reiterated at Overweight by Cantor Fitzgerald

Jan 12, 2026 07:25AM 'Our Top Pick Is Beam Therapeutics Inc (BEAM)'; PT Raised at Bernstein

Jan 12, 2026 04:04AM Beam Therapeutics reaches FDA alignment on accelerated approval pathway

Jan 7, 2026 12:40AM UBS Starts Beam Therapeutics Inc (BEAM) at Neutral

Nov 17, 2025 09:15AM Benchmark Reiterates Speculative Buy Rating on Beam Therapeutics Inc (BEAM)

Nov 4, 2025 03:27PM Beam Therapeutics Inc. (BEAM) spreader of 5K contracts of February 25 and 35 calls as share price down 5.5%

Nov 4, 2025 08:02AM Beam, Inc. (BEAM) Misses Q3 EPS by 5c

Oct 31, 2025 09:54AM FDA Clears Way for Faster Personalized Gene Editing Treatments

Oct 9, 2025 12:12PM Jefferies Starts Beam Therapeutics Inc (BEAM) at Buy

Sep 15, 2025 07:33AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations

Aug 19, 2025 06:56AM Cantor Fitzgerald Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)

Aug 14, 2025 07:00AM Beam Therapeutics receives FDA RMAT designation for BEAM-101 therapy

Aug 5, 2025 12:49PM Clear Street Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jul 1, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jun 18, 2025 12:15PM CRISPR Therapeutics (CRSP) gains on continued chatter

Jun 17, 2025 11:28AM Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital

Jun 16, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jun 13, 2025 07:00AM Beam Therapeutics Inc. (BEAM) Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101

Jun 3, 2025 07:00AM Beam Therapeutics Inc. (BEAM) Granted FDA Orphan Drug Designation for BEAM-101

May 29, 2025 04:02PM Beam Therapeutics (BEAM) Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 12, 2025 04:05PM Beam (BEAM) Announces U.S. FDA RMAT Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 6, 2025 07:36AM Beam, Inc. (BEAM) Misses Q1 EPS by 3c

Apr 22, 2025 03:20PM Beam Therapeutics Inc. (BEAM) 10K contracts of August 20 puts trade

Apr 10, 2025 05:32AM Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'

Apr 7, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Mar 28, 2025 06:19AM BofA Securities Upgrades Beam Therapeutics Inc (BEAM) to Buy

Mar 27, 2025 04:01PM Beam Therapeutics (BEAM) Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency

Mar 25, 2025 09:44AM Bernstein SocGen Group Reiterates Outperform Rating on Beam Therapeutics Inc (BEAM)

Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma

Mar 13, 2025 04:26AM Beam Therapeutics Inc (BEAM) PT Raised to $64 at Citi

Mar 11, 2025 10:22AM Bernstein Reiterates Outperform on Beam Therapeutics Inc (BEAM) Amid Positive AATD Data

Mar 11, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Mar 10, 2025 12:59PM Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy

Mar 10, 2025 12:58PM Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)

Mar 10, 2025 11:36AM Scotiabank Upgrades Beam Therapeutics Inc (BEAM) to Sector Outperform

Mar 10, 2025 06:24AM Beam Therapeutics Inc. (BEAM) Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency

Mar 10, 2025 06:22AM Beam Therapeutics Inc. (BEAM) Prices 16.15M Share Offering at $28.48/sh

Mar 3, 2025 06:55AM Beam Therapeutics Inc (BEAM) PT Raised to $25 at Scotiabank

Mar 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Feb 25, 2025 04:33PM Beam, Inc. (BEAM) Tops Q4 EPS by 18c

Feb 14, 2025 11:00AM Increasing unusual option volume: GT FROG KC FITB CNR VNET ABSI BEAM

Feb 11, 2025 07:07AM BMO Capital on Beam Therapeutics Inc (BEAM): 'AATD Readout in 1H25 Could Move BEAM 50-100%+'

Feb 3, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jan 23, 2025 07:00AM Beam Therapeutics (BEAM) to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025 07:04AM Beam Therapeutics Inc. (BEAM) Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Jan 8, 2025 06:00PM Bernstein's top two SMID biotech picks for 2025

Jan 6, 2025 02:00PM 7 top biotech picks for 2025 according to Wells Fargo

Dec 9, 2024 01:42PM BMO Capital Reiterates Outperform Rating on Beam Therapeutics Inc (BEAM)

View Older Stories